title: Benefits of nocturnal nasal CPAP in patients with cystic fibrosis.
abstract: Patients with cystic fibrosis (CF) often hypoventilate during sleep with marked falls in oxygen saturation (SaO2%). This occurs most commonly during REM sleep, when there is a reduction in rib cage excursion and a fall in end-expiratory lung volume (EELV). The aim of this study was to examine the effect of nocturnal nasal continuous positive airway pressure (nCPAP) on SaO2 and the respiratory disturbance index (RDI) during sleep in patients with CF and severe lung disease. Seven patients (FEV1% pred, 23 +/- 5; range, 14 to 28%) were evaluated during sleep on two nights, control and nCPAP (11 +/- 2 cm H2O; range, 8 to 16 cm H2O), with four patients breathing room air and three patients breathing supplemental oxygen on both nights. Mean awake SaO2 was 91 +/- 1% (range, 89 to 93%). All patients showed significant oxyhemoglobin desaturation and respiratory disturbance in the control study. The maximal falls in SaO2 (15 +/- 10%) were most often associated with phasic eye movements, and a decline in rib cage excursion and the sum signal (Respitrace) during REM sleep. Nasal CPAP resulted in a significant improvement in the mean minimum oxygen saturation (MMOS) during both NREM (nCPAP 91 +/- 3% vs control 88 +/- 2%, p < 0.05) and REM sleep (nCPAP 89 +/- 6% vs control 83 +/- 6%, p < 0.05). Transcutaneous CO2 measurements were not significantly different between the control and the nCPAP studies. The RDI was also significantly reduced with nCPAP especially during REM sleep (9 +/- 7 events per hour vs control 25 +/- 11 events per hour, p < 0.05). Nasal CPAP caused no change in total sleep time or sleep efficiency yet significantly reduced the RDI and improved baseline SaO2 during both NREM and REM sleep.
authors.affiliation: Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
authors.forename: J A
authors.initials: JA
authors.lastname: Regnis
authors.forename: A J
authors.initials: AJ
authors.lastname: Piper
authors.forename: K G
authors.initials: KG
authors.lastname: Henke
authors.forename: S
authors.initials: S
authors.lastname: Parker
authors.forename: P T
authors.initials: PT
authors.lastname: Bye
authors.forename: C E
authors.initials: CE
authors.lastname: Sullivan
mesh_terms: D000293:Adolescent; D000328:Adult; D003550:Cystic Fibrosis / Q000097:blood / Q000503:physiopathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D010100:Oxygen / Q000097:blood; D010108:Oxyhemoglobins / Q000032:analysis; D017286:Polysomnography; D011175:Positive-Pressure Respiration; D012119:Respiration / Q000502:physiology; D012895:Sleep, REM / Q000502:physiology
chemical_list: D010108:Oxyhemoglobins; D010100:Oxygen